HER2 Support Group Forums - View Single Post - Polyclonal antibodies: explained by company with preclinical products

Rich66 · 05-19-2009, 07:27 PM

1: Expert Opin Biol Ther. 2009 Jan;9(1):97-110. Links: A pan-HER approach for cancer therapy: background, current status and future development.

Huang Z, Brdlik C, Jin P, Shepard HM.
Receptor BioLogix, Inc., Palo Alto, CA 94303, USA.
BACKGROUND: The human EGF receptor (EGFR or HER) family and its cognate ligands contribute significantly to the aggressiveness of many human malignancies, and are therefore therapeutic targets with great clinical potential. OBJECTIVE: Currently approved single-targeted agents, like mAbs, (e.g., trastuzumab, cetuximab, or pertuzumab) or small-molecule tyrosine kinase inhibitors (TKIs, e.g., gefinitib and erlotinib), are limited by their exquisite specificity (mAbs) or lack thereof (TKIs). Therefore, therapeutics are needed that target multiple HER family members and HER ligands to circumvent these limitations. METHODS: We summarize therapeutic mechanisms of action, analyze tumor resistance to current anti-HER therapies, and introduce a novel pan-HER ligand sequestering agent for cancer treatment. CONCLUSION: RB200, a bispecific (EGFR/HER3) ligand binding trap, has been developed to address the need for a pan-HER therapy in human cancer.

05-19-2009, 07:27 PM	#2
Rich66 Senior Member Join Date: Feb 2008 Location: South East Wisconsin Posts: 3,431	1: Expert Opin Biol Ther. 2009 Jan;9(1):97-110. Links A pan-HER approach for cancer therapy: background, current status and future development. Huang Z, Brdlik C, Jin P, Shepard HM. Receptor BioLogix, Inc., Palo Alto, CA 94303, USA. BACKGROUND: The human EGF receptor (EGFR or HER) family and its cognate ligands contribute significantly to the aggressiveness of many human malignancies, and are therefore therapeutic targets with great clinical potential. OBJECTIVE: Currently approved single-targeted agents, like mAbs, (e.g., trastuzumab, cetuximab, or pertuzumab) or small-molecule tyrosine kinase inhibitors (TKIs, e.g., gefinitib and erlotinib), are limited by their exquisite specificity (mAbs) or lack thereof (TKIs). Therefore, therapeutics are needed that target multiple HER family members and HER ligands to circumvent these limitations. METHODS: We summarize therapeutic mechanisms of action, analyze tumor resistance to current anti-HER therapies, and introduce a novel pan-HER ligand sequestering agent for cancer treatment. CONCLUSION: RB200, a bispecific (EGFR/HER3) ligand binding trap, has been developed to address the need for a pan-HER therapy in human cancer.